chrisvoncsefalvay/vaers-narrative-generation huggingface dataset:
Age: 54.0
Sex: M
Vaccine: COVID19
Symptoms: Hypoaesthesia, Insomnia, Paraesthesia, Quality of life decreased
Clinical narrative: burning in my extremities, moved up to myback, neck, and head.I can barely tolerated any sun light as I feelburning sensation over my body.; I have been experiencing sensation similar to electricalsensations going thru my body; I was not able to sleep; I am not able to exercise, run, or do a lotactivities that I used to do on my own.My quality of life is diminished.; weakness are still with me daily.; I received my 2nd dose on 01/202/2021, in the next 24-48 hours I began experiencing tingling and burning in my extremities, moved up to myback, neck, and head.; Thesesensations and numbness andweakness are still with me daily.; This is a spontaneous report from a contactable physician. A 54-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EL1283) via an unspecified route of administration in the left arm on 20Jan2021(at the age of 54-years-old) as a single dose for COVID-19 immunisation. Medical history included asthma. Concomitant medications included budesonide, formoterol fumarate (SYMBICORT INH) for unknown indication since unknown start date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the left arm on 29Dec2020(at the age of 54-years-old) as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 20Jan2021, the patient received 2nd dose, in next 24-48 hours the patient began experiencing tingling and burning in extremities. Eventually tingling and burning moved up to the back, neck, and head. The patient was not able to sleep as he had been experiencing sensation similar to electrical sensations going thru in his body. The patient can barely tolerate any sun light as he felt burning sensation over his body. These sensations and numbness and weakness are still present in him daily. The patient was not able to exercise, run, or do a lot activities that he used to do on his own. The patient's quality of life was diminished. The events resulted in doctor or other healthcare professional (number of specialists) office/clinic visit. Therapeutic measures were taken as a result of adverse events and included treatment with ELAVIL, LYRICA and prednisone (MANUFACTURER UNKNOWN). On an unknown date, the patient underwent MRI (brain/spine), CT scan and blood work, but the results were unspecified. The clinical outcome of event tingling, burning sensation, numbness, weakness, not able to exercise, run, or do a lot activities that he used to do on his own, quality of life was diminished, similar to electrical sensations, not able to sleep was not recovered at the time of this report.  No follow-up attempts are needed; No further information is expected.
Age: 51.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary pain, Malaise, Vaccination site pain
Clinical narrative: arm pit pain; Feeling unwell; Injection site pain; This is a spontaneous report from a contactable consumer, the patient. A 51-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 06Apr2021 at 17:15 (at the age of 51-year-old) as a single dose for COVID-19 immunisation. Medical history included hypertension. The patient did not have any allergies to medications, food, or other products. Concomitant medications included losartan (MANUFACTURER UNKNOWN) from unknown date and for unknown indication. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 06Apr2021, the patient experienced Injection site pain for 4 days, on 08Apr2021, after day 2, pain moved to arm pit and felt unwell on 07Apr2021, which is on day 2. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as the result of adverse events. The clinical outcome of the events Injection site pain was recovered on 10Apr2021, after the duration of 4 days and the events arm pit pain and feeling unwell was recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Breast swelling, Erythema, Skin warm, Tenderness
Clinical narrative: Swollen right breast; Warm to touch; Tender to the touch; Pink/redness; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old male patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm right on 18Mar2021 at 14:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included cholesterol and pollen allergy. Concomitant medications included rosuvastatin calcium (CRESTOR), calcium ascorbate (VITAMIN C), vitamin d nos (VITAMIN D) and multivitamin (MANUFACTURER UNKNOWN) for unknown indication. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 20Mar2021, the patient experienced swollen right breast, warm to touch, tender to the touch, pink/ redness. Therapeutic measures were not taken as a result of these events. The adverse events did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events warm to touch, tender to the touch, pink/ redness and swollen right breast were recovered on an unknown date in Mar2021. The patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration in the arm right on 08Apr2021 at 14:00 (at the age of 58-years-old) as a single dose for COVID-19 immunisation.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Sex: U
Vaccine: COVID19
Symptoms: Body temperature, Pyrexia
Clinical narrative: fever of 100 degrees; This is a spontaneous report from a contactable consumer, the patient. A patient of unknown age and unknown gender received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration in the left arm on 13Apr2021 at 17:45 as a single dose for COVID-19 immunisation. Medical history included blepharitis, baker's cyst, high cholesterol and osteoporosis from unknown date and unknown if ongoing. Concomitant medications included azithromycin (AZASITE), azelastine (MANUFACTURER UNKNOWN), doxycycline (MANUFACTURER UNKNOWN), dexamethasone, neomycin, polymyxin b (NEOPOLYDEX); all from unknown date for unspecified indication and more. The patient had no known allergies to medications, food or other products. The patient previously took first dose of BNT162B2(PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6207) via an unspecified route of administration in the left arm on 16Mar2021 at 12:15 as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 12:15, the patient experienced fever of 100 degrees. On 14Apr2021, the patient underwent body temperature and the result was 100 degrees. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The patient did not receive any treatment for the reported event.  The clinical outcome of the event fever of 100 degrees was recovering.  No follow-up attempts are needed. No further information is expected.
Age: 38.0
Sex: M
Vaccine: COVID19
Symptoms: Blood glucose increased
Clinical narrative: Elevated blood glucose levels for the past 48 hours,today being far worse than the previous.; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8729) via an unspecified route of administration in the left arm on 12Apr2021 at 14:15 (at the age of 38-year-old) as a single dose for COVID-19 immunisation. Medical history included type 1 diabetes mellitus. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient had no allergic to medications, food, or other products.   Concomitant medications included insulin aspart (NOVOLOG), amlodipine (MANUFACTURER UNKNOWN), bupropion hydrochloride (WELLBUTRIN), escitalopram (MANUFACTURER UNKNOWN) and insulin glargine (LANTUS) all taken for unknown indication on unknown date. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955,) via an unspecified route of administration in the left arm on 15Mar2021 at 14:15 as a single dose. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 13Apr2021 at 17:00, the patient experienced elevated blood glucose levels. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were taken as a result of events and included treatment with insulin.  Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event elevated blood glucose levels was resolving at the time of this report.     No follow-up attempts are needed. No further information is expected.
Sex: F
Vaccine: COVID19
Symptoms: Urticaria
Clinical narrative: Hives along left arm and they continued to show upon stomach, legs and arms afterwards; This is a spontaneous report from a contactable consumer, the patient. A non-pregnant female patient of unknown age received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the left arm on 25Mar2021 at 10:15 as a single dose for COVID-19 immunisation. The patient was allergic to bee sting and sting location will swell and be itchy for about a week. Prior to vaccination, patient was not diagnosed with COVID-19. Concomitant medications included ethinylestradiol, levonorgestrel (SRONYX) for birth control from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 28Mar2021, the patient developed hives along the left arm approximately three days after the first shot and they continued to show up on the stomach, legs and arms afterwards. The hives have not resolved and she was due for the second COVID vaccine shot on 15Apr2021. The event resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of hives and included treatment with OTC (over the counter) antihistamines (MANUFACTURER UNKNOWN). Since the vaccination, patient had not been tested for COVID-19. The clinical outcome of the event hives along the left arm approximately three days after the first shot and they continued to show up on the stomach, legs and arms afterwards was not recovered at the time of report.   No follow-up attempts are needed. No further information is expected.
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Dyspepsia, Feeding disorder, Headache, Lethargy, Nausea
Clinical narrative: Body ache; Lethargy; Heartburn; Difficulty eating due to nausea and heartburn; Headache; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 31Mar2021 at 10:45 hours (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included diabetes. The patient had no known allergies to medications, food or other products. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 04Apr2021 at 12:00, the patient experienced headache, body ache, lethargy, nausea, heartburn and difficulty eating due to nausea and heartburn. Starting 4 days after vaccination lasting 5 days. No therapeutic measures were taken as a result of reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event headache, body ache, lethargy, nausea, heartburn and difficulty eating due to nausea and heartburn was recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 58.0
Sex: M
Vaccine: COVID19
Symptoms: Pain
Clinical narrative: Body ache; Lethargy; Heartburn; Difficulty eating due to nausea and heartburn; Headache; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 58-year-old male patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 31Mar2021 at 10:45 hours (at the age of 58-years-old) as a single dose for COVID-19 immunisation. Medical history included diabetes. The patient had no known allergies to medications, food or other products. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. On 04Apr2021 at 12:00, the patient experienced headache, body ache, lethargy, nausea, heartburn and difficulty eating due to nausea and heartburn. Starting 4 days after vaccination lasting 5 days. No therapeutic measures were taken as a result of reported events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the event headache, body ache, lethargy, nausea, heartburn and difficulty eating due to nausea and heartburn was recovering at the time of this report.   No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 43.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Electric shock sensation, Pruritus
Clinical narrative: The first night that I got the vaccine I began to feel in my legs and arms like an electricity, burning and itching that today after 2 days I still have.; The first night that I got the vaccine I began to feel in my legs and arms like an electricity, burning and itching that today after 2 days I still have.; The first night that I got the vaccine I began to feel in my legs and arms like an electricity, burning and itching that today after 2 days I still have.; I also feel that burning in my face.; This is a spontaneous report from a contactable consumer, the patient. A 43-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: 620-099) via an unspecified route of administration in the arm left on 12Apr2021 at 13:15 (at the age of 43-year-old) as a single dose for COVID-19 immunisation. Medical history included fibromyalgia and migraines. Concomitant medications included gabapentin (MANUFACTURER UNKNOWN) 100mg for unknown indication from an unknown date. The patient previously received scopolamine (MANUFACTURER UNKNOWN) for unknown indication on an unknown date and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID-19 vaccine. On 12Apr2021, the first night of the vaccine the patient began to feel in legs and arms like an electricity, burning and itching even after 2 days. Sometimes the patient also felt that burning in the face. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events feel in legs and arms like an electricity, burning, Itching and feel that burning in face was not recovered at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Arthralgia, Gait disturbance, Musculoskeletal stiffness
Clinical narrative: Pain and soreness around my rightankle; stiffness; Difficulty walking; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: Er8732) via an unspecified route of administration in the right arm on 13Apr2021 at 08:45 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. Medical history included high blood pressure, cholesterol and anxiety. Concomitant medications were not reported. The patient did not receive any other vaccine within four weeks prior to the COVID-19 vaccine. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. On 14Apr2021 at 08:00, the patient experienced pain and soreness around right ankle, stiffness and difficulty walking. The patient did not receive any treatment for the events. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. The clinical outcome of the events pain and soreness around right ankle, stiffness and difficulty walking were recovering at the time of this report.  No follow-up attempts are needed. No further information is expected.
Age: 61.0
Sex: F
Vaccine: COVID19
Symptoms: Epistaxis
Clinical narrative: Profuse nose bleed 4 days after first vaccination; This is a spontaneous report from a contactable consumer, the patient. A 61-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8732) via an unspecified route of administration in the right arm on 10Apr2021 at 09:45 (at the age of 61-years-old) as a single dose for COVID-19 immunisation. Medical history included two and half parathyroid glands removed in 2015 with no cancer involvement. Concomitant medications included calcium (MANUFACTURER UNKNOWN) and multivitamin (MANUFACTURER UNKNOWN) taken for unknown indication from unknown date and unknown if ongoing. The patient previously received codeine (MANAFACTURER UNKNOWN) on an unknown date and experienced drug allergy. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 14Apr2021 at 11:15, the patient experienced profuse nose bleed four days after the first vaccination. This occurred while bending over looking in refrigerator. This was not common and the patient never had a nose bleed like that before. This took approximately 20 minutes to stop and the patient was wondering  if this was possibly related to her vaccination or if this had occurred with other patients. It was reported that she was recovering but if it recurred she might need an additional assistance. The event did not result in doctor/other health care professional office/ clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the event. The clinical outcome of the event profuse nose bleed 4 days after first vaccination was recovering at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 60.0
Sex: F
Vaccine: COVID19
Symptoms: Vitreous floaters
Clinical narrative: Sudden development of eye floater; This is a spontaneous report from a contactable consumer, the patient. A 60-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER2613) via an unspecified route of administration in the right arm on 23Mar2021 at 10:15 (at the age of 60-years-old) as a single dose for COVID-19 immunisation. The patient medical history included allergies. The patient had known allergies. Concomitant medications included levocetirizine dihydrochloride (XYZAL) for allergies. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6202) via an unspecified route of administration in the right arm on 02Mar2021 at 11:30 as a single dose for COVID-19 immunisation. On 27Mar2021 at 12:00, the patient experienced sudden development of eye floater. The event resulted in doctor or other healthcare professional office/clinic visit. No therapeutic measures were taken as a result of reported event. The clinical outcome of the event eye floaters was recovered with sequelae on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 56.0
Sex: F
Vaccine: COVID19
Symptoms: Cardiac discomfort, Dry mouth, Paraesthesia
Clinical narrative: Pins needles; dry mouth; mild heart pressure; This is a spontaneous report from a contactable consumer, the patient. A 56-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EWO151) via an unspecified route of administration in the left arm on 10Apr2021 at 12:00 (at the age of 56-years-old) as a single dose for COVID-19 immunisation. The patient did not have any relevant medical history. Concomitant medications were not reported. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 10Apr2021, the patient experienced pins and needles, dry mouth and mild heart pressure. The events did not result in a visit to the doctors or other healthcare professional office/clinic visit and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event pins and needles, dry mouth and mild heart pressure were unknown at the time of this report.  No follow-up attempts are needed. No further information is expected.
Sex: U
Vaccine: COVID19
Symptoms: Malaise
Clinical narrative: not feeling well; This is a spontaneous report from a contactable consumer. An unknown gender patient of unknown age received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot number: Unknown) via an unspecified route of administration on 13Apr2021 as a single dose for COVID-19 immunisation. Medical history and concomitant medications were not reported. Prior to vaccination, it was unknown whether the patient was diagnosed with COVID-19. Since the vaccination, it was unknown whether the patient had been tested for COVID-19. It was unknown whether the patient received any other vaccines within four weeks prior to the vaccination. On 14Apr2021, well within 24 hours of the vaccination, the patient was not feeling well. It was unknown whether therapeutic measures were taken as a result of the event. The clinical outcome of the event not feeling well was unknown at the time of this report.  No follow-up attempts are needed; information about lot/batch number cannot be obtained.
Age: 53.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary mass, Lymphadenopathy, Pain in extremity, SARS-CoV-2 test, Tenderness
Clinical narrative: Lemon-size lump palpable and visible in left armpit; Although retained full range of motion in left arm/shoulder, area was tender and sore.; Although I retained full range of motion in left arm/shoulder, area was tender and sore.; Lemon-size lump palpable and visible in left armpit. Although lymphatic reactions know side effect, as a 2-yr breast cancer survivor, a lump was alarming; This is a spontaneous report from a contactable consumer, the patient. A 53-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6208), via an unspecified route of administration in the left arm on 27Mar2021 (at the age of 53-years-old), as a single dose for COVID-19 immunisation. Medical history included chronic migraine, gastroesophageal reflux disease, breast cancer, lymphedema (Stage 0), lumpectomy and radiation therapy on an unknown date in 2019, pituitary macroadenoma, herpes simplex type I/II. The patient had known allergies to shell fish (crustaceans), sulfonamide allergy, environmental allergy and fruit allergy (tomatoes). The patient receives unspecified medications in two weeks of vaccination. The patient previously took prednisone and codeine; both on unknown dates for unspecified indications and experienced drug allergy. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6198), via an unspecified route of administration in the left arm on 05Mar2021 at 15:30 (at the age of 53-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 28Mar2021 at 19:00, approx. 36 hours following shot, the patient experienced lemon-size lump palpable and visible in left armpit, although lymphatic reactions know side effect, as a 2-year breast cancer survivor, a lump was alarming. Although the patient retained full range of motion in left arm/shoulder, area was tender and sore. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were taken as a result of the events which included physical therapy and lymphatic massage over a two-week period that eased the concern. On 01Apr2021, the patient underwent lab tests and procedures which included SARS-CoV-2 test (nasal swab) and the result was negative. The clinical outcome of the events lemon-size lump palpable and visible in left armpit, although lymphatic reactions know side effect, as a 2-year breast cancer survivor, a lump was alarming, retained full range of motion in left arm/shoulder, area was tender and sore were resolving at the time of this report.    No follow-up attempts are needed. No further information is expected.
Age: 45.0
Sex: F
Vaccine: COVID19
Symptoms: Headache, Lymphadenopathy
Clinical narrative: Odd swollen lymph node above collarbone on left side of neck noticed on day 9 after shot (same side as injection) & headaches in the morning 3 or 4 of last 10 days.; Odd swollen lymph node above collarbone on left side of neck noticed on day 9 after shot (same side as injection) & headaches in the morning 3 or 4 of last 10 days.; This is a spontaneous report from a non-contactable consumer, the patient. A 45-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8737) via an unspecified route of administration in the left arm on 01Apr2021 at 15:45 (at the age of 45-years-old) as a single dose for COVID-19 immunisation. Medical history included pituitary disorder (reported as Pituitary gland condition). The patient had no known allergies to medications, food, or other products. Concomitant medications taken within two weeks of vaccination. included ibuprofen (MANUFACTURER UNKNOWN), famotidine (MANUFACTURER UNKNOWN), both for unknown indication from unknown date and cortisone (MANUFACTURER UNKNOWN) (reported as cortisone shot) from unknown date for injury. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient experienced odd swollen lymph node above collarbone on left side of neck noticed on 09Apr2021, day nine after shot (same side as injection) and headaches in the morning 3 or 4 of last 10 days from an unknown date in Apr2021. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. No therapeutic measures were taken as a result of the events. The clinical outcome of the events odd swollen lymph node above collarbone on left side of neck noticed on day 9 after shot (same side as injection) and headaches in the morning 3 or 4 of last 10 days was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Sex: M
Vaccine: COVID19
Symptoms: Hypoaesthesia
Clinical narrative: entire arm is numb and he cannot lift it up; This is a spontaneous report received from a contactable consumer from Pfizer Sponsored program. This consumer (patient's wife) reported for a male patient (reporter's husband) of an unspecified age received bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, Formulation: solution for injection, Lot number and Expiration date was not reported), via an unspecified route of administration on an unspecified date (time around 10:00) as dose number unknown, single for covid-19 immunisation. The patient medical history and concomitant medications were not reported. Reporter stated that her husband had the first dose of Pfizer's COVID vaccine on an unknown date around 10:00 and his "entire arm is numb and he cannot lift it up". Reporter was asking what you recommend for him. Reporter was reluctant to transfer as she stated she should had gone to the ER (emergency room) instead of calling. The outcome of the event was unknown.  No follow-up attempts are needed; information about lot/batch number cannot be obtained
Age: 38.0
Sex: F
Vaccine: COVID19
Symptoms: Dysmenorrhoea, Heavy menstrual bleeding
Clinical narrative: Heavy period with painful cramps; Heavy period with painful cramps; This is a spontaneous report from a contactable consumer, the patient. A 38-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot Number: ew0151), via an unspecified route of administration in the left arm on 07Apr2021 at 13:30 (at the age of 38-years-old), as a single dose for COVID-19 immunisation. Medical history included high blood pressure and migraines. The patient had known allergies to aloe vera and latex. Concomitant medications included ethinylestradiol, ferrous fumarate, norethisterone acetate (LO LOESTRIN FE), losartan potassium (MANUFACTURER UNKNOWN) and vitamin d nos (VITAMIN D); all from unknown dates for unspecified indications. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE, Lot number: en6207), via an unspecified route of administration in the left arm on 17Mar2021 at 13:00 (at the age of 38-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 12Apr2021 at 03:00, after 5 days of vaccination the patient experienced heavy period with painful cramps. It was reported that, due to being on birth control the patient had no longer menstruate. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the event heavy period with painful cramps was not resolved at the time of reporting.   No follow-up attempts are needed. No further information is expected.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Axillary mass, Dysphagia, Headache, Neck pain, Swelling
Clinical narrative: Swollen neck/collarbone area; Sore side of neck/collarbone area,; Presence of knots in this area with sore to touch and move neck area/knot under left arm pit with feeling ofsmall knot; Difficult swallowing; Constant headache; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE;Lot Number: ER2613) via an unspecified route of administration in the arm left on 10Apr2021 at 14:15(at the age of 50-year-old) as a single dose for COVID-19 immunisation. The patient did not receive any medication within two weeks of vaccination. The patient previously took Sulphur and experienced drug allergy. The patient previously received first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EN6205) via an unspecified route of administration in the arm left on 14Mar2021 at 14:15 as a single dose for COVID-19 immunisation. Prior to vaccination, the patient was not diagnosed with COVID -19.Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 11Apr2021 at 17:30 the patient experienced swollen neck/collarbone area, sore side of neck/collarbone area, presence of knots in this area with sore to touch and move neck area/knot under left arm pit with feeling of small knot, difficult swallowing and constant headache. The event resulted in emergency room/department or urgent care. The clinical outcome of the events swollen neck/collarbone area, sore side of neck/collarbone area, presence of knots in this area with sore to touch and move neck area/knot under left arm pit with feeling of small knot, difficult swallowing and constant headache was not recovered at the time of the report.   No follow-up attempts are needed. No further information is expected.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Back pain, Dehydration, Headache, Lymphadenopathy, Nausea
Clinical narrative: Night sweats; Sense of dehydration; Back pain; swollen lymph nodes under armpit; Fever; Terrible headache; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 65-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 08Apr2021 at 10:30 (at the age of 65-year-old) as a single dose for COVID-19 immunisation. Medical history included borderline for Sjogren's Syndrome and COVID-19 with pneumonia. The patient was allergic to yeast and corn (but patient consume).  The patient previously took prochlorperazine maleate (COMPAZINE) and levofloxacin (LEVAQUIN) for an unknown indication on an unknown date and experienced drug allergy. Concomitant medication included unspecified vitamins only from an unknown indication from an unknown date. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021 at 20:30, the patient experienced fever, swollen lymph nodes under armpit (same side of body as injection), night sweats, terrible headache, sense of dehydration, back pain and nausea began after 10 hours of vaccination. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Symptoms mostly abated 48 hrs later. The clinical outcome of events fever, swollen lymph nodes under armpit (same side of body as injection), night sweats, terrible headache, sense of dehydration, back pain and nausea were recovered on 10 Apr2021.  No follow-up attempts are possible, information about lot/batch number cannot be obtained.
Age: 65.0
Sex: F
Vaccine: COVID19
Symptoms: Night sweats, Pyrexia
Clinical narrative: Night sweats; Sense of dehydration; Back pain; swollen lymph nodes under armpit; Fever; Terrible headache; Nausea; This is a spontaneous report from a contactable consumer, the patient. A 65-year-old non-pregnant female patient received BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: UNKNOWN) via an unspecified route of administration on 08Apr2021 at 10:30 (at the age of 65-year-old) as a single dose for COVID-19 immunisation. Medical history included borderline for Sjogren's Syndrome and COVID-19 with pneumonia. The patient was allergic to yeast and corn (but patient consume).  The patient previously took prochlorperazine maleate (COMPAZINE) and levofloxacin (LEVAQUIN) for an unknown indication on an unknown date and experienced drug allergy. Concomitant medication included unspecified vitamins only from an unknown indication from an unknown date. Prior to vaccination, the patient was diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021 at 20:30, the patient experienced fever, swollen lymph nodes under armpit (same side of body as injection), night sweats, terrible headache, sense of dehydration, back pain and nausea began after 10 hours of vaccination. The events resulted in doctor or other healthcare professional office/clinic visit. Therapeutic measures were not taken as a result of the events. Symptoms mostly abated 48 hrs later. The clinical outcome of events fever, swollen lymph nodes under armpit (same side of body as injection), night sweats, terrible headache, sense of dehydration, back pain and nausea were recovered on 10 Apr2021.  No follow-up attempts are possible, information about lot/batch number cannot be obtained.
Age: 50.0
Sex: F
Vaccine: COVID19
Symptoms: Lymph node pain
Clinical narrative: Left neck lymph node going to explode; This is a spontaneous report from a contactable consumer, the patient. A 50-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE;  Lot Number: er8732) via an unspecified route of administration in the left arm on 30Mar2021 at 14:00 (at the age of 50-year-old) as a single dose for COVID-19 immunisation. Medical history included spontaneous coronary artery dissection (SCAD), thyroid and pseudocholinesterase deficiency. The patient has known allergy to  PCN (penicillin), sulfa, Macrobid, Neosporin and cat gut stitches. Concomitant medications included acetylsalicylic acid (MANUFACTURER UNKNOWN), levothyroxine (MANUFACTURER UNKNOWN), fluconazole (DIFLUCAN), vitamin D (MANUFACTURER UNKNOWN) and probiotics (MANUFACTURER UNKNOWN) all for unknown indication from an unknown date and unknown if ongoing. The patient did not receive any other vaccines within four weeks prior to the vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. On 30Mar2021, same day of vaccination, 45 minutes after jab in left arm, the patient experienced left neck lymph node going to explode. It felt hot and cold concurrently or like something was piercing it. She experienced super odd never before felt sensation and it subsided after about 3 days but again 2 weeks later the patient was still aware of it. It did not hurt but definitely did not feel 100% normal. It was never swollen (like they would have been normally swell a little when she would get a cold or something but it didn't even do that). Therapeutic measures were not taken as a result of the event. The event did not result in a visit to the doctors or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Since the vaccination, the patient had not been tested for COVID-19. The clinical outcome of the event left neck lymph node going to explode was recovered with sequelae on an unknown date in 2021.   No follow-up attempts are needed. No further information is expected.
Age: 55.0
Sex: M
Vaccine: COVID19
Symptoms: Chills, Fatigue, Pain, Pyrexia, SARS-CoV-2 test
Clinical narrative: Achy; Slight fever; Chills; Fatigue; This is a spontaneous report from a contactable consumer, the patient. A 55-year-old male patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 07Apr2021 at 09:30 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. Other medical history not reported. The patient had no known allergies to medications, food, or other products. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any medications within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EP6955) via an unspecified route of administration in the left arm on 17Mar2021 at 13:30 (at the age of 55-years-old) as a single dose for COVID-19 immunisation. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021 at 01:30, approximately 12 hours after initial dose, the patient experienced achy, slight fever, chills and fatigue. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. Since the vaccination, the patient had been tested for COVID-19. On 14Apr2021, the patient underwent lab tests and procedures which included nasal swab test and the result was pending. The clinical outcome of the events achy, slight fever, chills and fatigue was recovered on an unknown date in Apr2021.  No follow-up attempts are needed. No further information is expected.
Age: 70.0
Sex: F
Vaccine: COVID19
Symptoms: Oral herpes
Clinical narrative: Within a week of receiving the first vaccine, an oral herpes outbreak occured. When received the second dose the outbreak occured within hours. Have had these outbreaks for years usually 1 or 2x per year; This is a spontaneous report from a contactable consumer, the patient. A 70-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727), via an unspecified route of administration in the left arm on 24Mar2021 at 10:00 (at the age of 70-years-old) and a second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8731), via an unspecified route of administration in the left arm on 14Apr2021 (at the age of 70-years-old), as a single dose for COVID-19 immunisation. Medical history included non-Hodgkin's lymphoma and it was in remission for 4 years. The patient did not have any allergies to medications, food or other products. Concomitant medications included valaciclovir (VALACYCLOVIR) 1000 mg, trazodone (MANUFACTURER UNKNOWN) 100 mg and estrogen nos (BIOIDENTICAL); all from unknown dates for unspecified indications. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On an unknown date in Mar2021, within a week of receiving the first vaccine, the patient experienced an oral herpes outbreak. On 14Apr2021, when the patient received the second dose, the outbreak occurred within hours. The patient usually had these outbreaks once or twice a year. It was reported that the patient took valacyclovir both the times. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room/department or urgent care. Therapeutic measures were taken as a result of the event which included treatment with valacyclovir. The clinical outcome of the event within a week of receiving the first vaccine, an oral herpes outbreak occurred, when received the second dose the outbreak occurred within hours was resolving at the time of this report.   No follow-up attempts are needed. No further information is expected.
Age: 46.0
Sex: F
Vaccine: COVID19
Symptoms: Chills, Fatigue, Myalgia
Clinical narrative: After 2nd dose:  Chills, muscle aches, fatigue on the next day.; muscle ache; fatigue; This is a spontaneous report from a non-contactable consumer, the patient. A 46-year-old non-pregnant female patient received the second dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: EW0162) via an unspecified route of administration on 09Apr2021(at the age of 46-years-old), as a single dose for COVID-19 immunisation. Medical history was reported as none. The patient did not receive any medications within two weeks of vaccination. The patient previously received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8727) via an unspecified route of administration on 17Mar2021 (at the age of 46-years-old), as a single dose for COVID-19 immunisation. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. The patient had no allergies to medications, food, or other products. On 10Apr2021, after second dose, the patient experienced chills, muscle aches, fatigue on the next day. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events chills, muscle aches and fatigue was recovered on unknown date in Apr2021.   No follow-up attempts are possible. No further information is expected.
Age: 40.0
Sex: F
Vaccine: COVID19
Symptoms: Burning sensation, Neuralgia, Pain, Pain in extremity
Clinical narrative: Burning in arms; Constant pain in arms; Believes pain in neurological; Burning pain in legs; About 2 days after vaccine I experienced increasing pain in legs; This is a spontaneous report from a contactable consumer, the patient. A 40-year-old non-pregnant female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: GR8737) via an unspecified route of administration in the left arm on 06Apr2021 at 08:15 (at the age of 40-year-old) as a single dose for COVID-19 immunisation. Medical history included type 1 diabetes mellitus and anemia. The patient had no known allergies. Concomitant medications included insulin human, insulin human injection, isophane (NOVOLIN 70/30 INSULIN) from unknown date and unknown if ongoing. Prior to the vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 08Apr2021, about 2 days after vaccine, the patient experienced increasing pain in legs. On 10Apr2021 had burning pain in legs and on 14Apr2021 has constant pain and burning in arms. The patient visited the doctor and doctor believed pain was neurological. The patient had type 1 diabetes and had never experienced any neuropathy pain before. Therapeutic measures were taken as a result of events and included treatment with TYLENOL. The events resulted in doctor or other healthcare professional office/clinic visit. Since the vaccination, the patient had not been tested for COVID-19.  The clinical outcome of the events increasing pain in legs, burning pain in legs, constant pain burning in arms and pain was neurological was not recovered at the time of the report.  No follow-up attempts are needed. No further information is expected.